Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)
- Author
- THATCHER, N1 ; CLARK, P. I; SMITH, D. B; ANDERSON, H1 ; GIRLING, D. J; MACHIN, D; STEPHENS, R. J; LALLEMAND, G; JENKINS, B
[1] Wythenshawe hosp., Manchester, United Kingdom - Conference title
- Association of Head and Neck Oncologists of Great Britain. Annual general meeting
- Conference name
- Association of Head and Neck Oncologists of Great Britain. Annual general meeting (1995-04-28)
- Author (monograph)
- Association of Head and Neck Oncologists of Great Britain, United Kingdom (Funder/Sponsor)
- Source
Clinical oncology (Springer. Print). 1995, Vol 7, Num 5, pp 293-299 ; ref : 13 ref
- ISSN
- 0936-6555
- Scientific domain
- Medical oncology
- Publisher
- Elsevier, Amsterdam
- Publication country
- Netherlands
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Agent alkylant Anthracyclines Anticancéreux Association médicamenteuse Bronchopulmonaire Chimiothérapie Cyclophosphamide Cytokine DNA topoisomerase (ATP-hydrolysing) Doxorubicine Epithélioma petite cellule Essai clinique phase II Etoposide Facteur stimulant colonie granulocyte Filgrastime Homme Inhibiteur enzyme Rythme administration Résultat Toxicité Traitement Podophyllotoxine dérivé Appareil respiratoire pathologie Bronche pathologie Enzyme Isomerases Poumon pathologie Tumeur maligne
- Keyword (en)
- Alkylating agent Anthracyclins Antineoplastic agent Drug combination Bronchopulmonary Chemotherapy Cytokine DNA topoisomerase (ATP-hydrolysing) Oat cell carcinoma Phase II trial Granulocyte colony stimulating factor Human Enzyme inhibitor Administration schedule Result Toxicity Treatment Respiratory disease Bronchus disease Enzyme Isomerases Lung disease Malignant tumor
- Keyword (es)
- Agente alquilante Antraciclinas Anticanceroso Asociación medicamentosa Broncopulmonar Quimioterapia Citoquina DNA topoisomerase (ATP-hydrolysing) Carcinoma célula de avena Ensayo clínico fase II Factor estimulante colonia granulocito Hombre Inhibidor enzima Ritmo administración Resultado Toxicidad Tratamiento Aparato respiratorio patología Bronquio patología Enzima Isomerases Pulmón patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 3705025
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0936-6555(05)80536-9 
https://dx.doi.org/10.1016/S0936-6555(05)80536-9
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0936-6555(05)80536-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Clinical oncology (Springer. Print)\";s:9:\"\u0000*\u0000stitle\";s:30:\"Clin. oncol. (Springer, Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:1:\"7\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"293\";s:8:\"\u0000*\u0000epage\";s:3:\"299\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0936-6555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"THATCHER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"CLARK, P. I\";i:1;s:11:\"SMITH, D. B\";i:2;s:11:\"ANDERSON, H\";i:3;s:13:\"GIRLING, D. J\";i:4;s:9:\"MACHIN, D\";i:5;s:14:\"STEPHENS, R. J\";i:6;s:12:\"LALLEMAND, G\";i:7;s:10:\"JENKINS, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Association of Head and Neck Oncologists of Great Britain. Annual general meeting\";s:8:\"\u0000*\u0000title\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0936-6555(05)80536-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Clinical oncology (Springer. Print)\";s:9:\"\u0000*\u0000stitle\";s:30:\"Clin. oncol. (Springer, Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:1:\"7\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"293\";s:8:\"\u0000*\u0000epage\";s:3:\"299\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0936-6555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"THATCHER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"CLARK, P. I\";i:1;s:11:\"SMITH, D. B\";i:2;s:11:\"ANDERSON, H\";i:3;s:13:\"GIRLING, D. J\";i:4;s:9:\"MACHIN, D\";i:5;s:14:\"STEPHENS, R. J\";i:6;s:12:\"LALLEMAND, G\";i:7;s:10:\"JENKINS, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Association of Head and Neck Oncologists of Great Britain. Annual general meeting\";s:8:\"\u0000*\u0000title\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0936-6555(05)80536-9\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0936-6555(05)80536-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Clinical oncology (Springer. Print)\";s:9:\"\u0000*\u0000stitle\";s:30:\"Clin. oncol. (Springer, Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:1:\"7\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"293\";s:8:\"\u0000*\u0000epage\";s:3:\"299\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0936-6555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"THATCHER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"CLARK, P. I\";i:1;s:11:\"SMITH, D. B\";i:2;s:11:\"ANDERSON, H\";i:3;s:13:\"GIRLING, D. J\";i:4;s:9:\"MACHIN, D\";i:5;s:14:\"STEPHENS, R. J\";i:6;s:12:\"LALLEMAND, G\";i:7;s:10:\"JENKINS, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Association of Head and Neck Oncologists of Great Britain. Annual general meeting\";s:8:\"\u0000*\u0000title\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0936-6555(05)80536-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Clinical oncology (Springer. Print)\";s:9:\"\u0000*\u0000stitle\";s:30:\"Clin. oncol. (Springer, Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:1:\"7\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"293\";s:8:\"\u0000*\u0000epage\";s:3:\"299\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0936-6555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"THATCHER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"CLARK, P. I\";i:1;s:11:\"SMITH, D. B\";i:2;s:11:\"ANDERSON, H\";i:3;s:13:\"GIRLING, D. J\";i:4;s:9:\"MACHIN, D\";i:5;s:14:\"STEPHENS, R. J\";i:6;s:12:\"LALLEMAND, G\";i:7;s:10:\"JENKINS, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Association of Head and Neck Oncologists of Great Britain. Annual general meeting\";s:8:\"\u0000*\u0000title\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0936-6555(05)80536-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Clinical oncology (Springer. Print)\";s:9:\"\u0000*\u0000stitle\";s:30:\"Clin. oncol. (Springer, Print)\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:1:\"7\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"293\";s:8:\"\u0000*\u0000epage\";s:3:\"299\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0936-6555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"THATCHER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"CLARK, P. I\";i:1;s:11:\"SMITH, D. B\";i:2;s:11:\"ANDERSON, H\";i:3;s:13:\"GIRLING, D. J\";i:4;s:9:\"MACHIN, D\";i:5;s:14:\"STEPHENS, R. J\";i:6;s:12:\"LALLEMAND, G\";i:7;s:10:\"JENKINS, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Association of Head and Neck Oncologists of Great Britain. Annual general meeting\";s:8:\"\u0000*\u0000title\";s:237:\"Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF ; filgrastim) in the treatment of small cell lung cancer (SCLC)\";s:8:\"\u0000*\u0000place\";s:9:\"Amsterdam\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
